Genta CLL Agent Genasense Has Not Shown Clinical Benefit, FDA Panel Says

Committee votes seven to three that data from Genta’s randomized trial of the chronic lymphocytic leukemia therapy does not represent substantial evidence of clinical benefit during Sept. 6 meeting.